EP Patent

EP4326246A4 — Psma-targeting ligands with optimal properties for imaging and therapy

Assigned to Wisconsin Alumni Research Foundation · Expires 2026-04-15 · 0y expired

What this patent protects

Patent listed against lutetium-lu-177-vipivotide-tetraxetan.

Drugs covered by this patent

Patent Metadata

Patent number
EP4326246A4
Jurisdiction
EP
Classification
—
Expires
2026-04-15
Drug substance claim
No
Drug product claim
No
Assignee
Wisconsin Alumni Research Foundation
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.